There is provided a chimeric antigen receptor (CAR) comprising a CD19-binding domain which comprises a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences: CDR1 – GYAFSSS (SEQ ID No. 1); CDR2 – YPGDED (SEQ ID No. 2) CDR3 – SLLYGDYLDY (SEQ ID No. 3); and b) a light chain variable region (VL) having CDRs with the following sequences: CDR1 – SASSSVSYMH (SEQ ID No. 4); CDR2 – DTSKLAS (SEQ ID No. 5) CDR3 – QQWNINPLT (SEQ ID No. 6). There is also provided a cell comprising such a CAR, and the use of such a cell in the treatment of cancer, in particular a B cell malignancy.